CBR1抗体

+ +

•  

   

     Gel: 15%SDS-PAGE, Lysate: 40 μg, Lane 1-6: Mouse liver tissue, human fetal lung tissue, hela cells, mouse kidney tissue, human brain malignant glioma tissue, K562 cells, Primary antibody: P08016(CBR1 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P08016(CBR1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08016(CBR1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The carbonyl reductase 1 (CBR1) antibody is a tool used to detect and study the CBR1 enzyme, a member of the short-chain dehydrogenase/reductase (SDR) superfamily. CBR1 plays a critical role in metabolizing endogenous and exogenous carbonyl compounds, including prostaglandins, steroids, and xenobiotics like the chemotherapeutic agent doxorubicin. It catalyzes the NADPH-dependent reduction of reactive carbonyl groups, influencing drug efficacy, detoxification, and cellular stress responses. CBR1 is ubiquitously expressed, with high levels in the liver, heart, and kidneys, and is implicated in diseases such as cancer, neurodegenerative disorders, and metabolic syndromes.

CBR1 antibodies are widely utilized in research to investigate the enzyme's expression, localization, and function. In cancer studies, they help assess CBR1's role in chemoresistance, as elevated CBR1 activity may reduce the effectiveness of anthracycline drugs. In neurodegenerative contexts, CBR1 antibodies aid in exploring its involvement in detoxifying neurotoxic aldehydes linked to Alzheimer's or Parkinson's disease. Additionally, these antibodies are applied in metabolic disorder research, particularly in conditions like diabetic complications where carbonyl stress is elevated.

Available as monoclonal or polyclonal variants, CBR1 antibodies are optimized for techniques like Western blotting, immunohistochemistry, and ELISA. Their specificity and cross-reactivity (e.g., with rodent homologs) are validated for experimental accuracy. Overall, CBR1 antibodies serve as essential tools for elucidating the enzyme's pathophysiological roles and therapeutic potential.